KRM-II-81 is a positive allosteric modulator of the GABAA receptor. It is selective for the alpha2 and alpha3 subunits. KRM-II-81 displays anxiolytic, antidepressant and anticonvulsant effects. However, it has less adverse effects than some other GABAA PAMs: it has low to no sedation and no tolerance development.[2]
A study has also shown KRM-II-81 to be better at treating seizures than diazepam.[3]
References
- ^ "KRM-II-81".
- ^ Witkin, Jeffrey M.; Lippa, Arnold; Smith, Jodi L.; Jin, Xiaoming; Ping, Xingjie; Biggerstaff, Andrew; Kivell, Bronwyn M.; Knutson, Daniel E.; Sharmin, Dishary; Pandey, Kamal P.; Mian, Md Yeunus; Cook, James M.; Cerne, Rok (February 2022). "The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders". Pharmacology, Biochemistry, and Behavior. 213: 173321. doi:10.1016/j.pbb.2021.173321. ISSN 1873-5177. PMID 35041859. S2CID 245963990.
- ^ Knutson, Daniel E.; Smith, Jodi L.; Ping, Xingjie; Jin, Xiaoming; Golani, Lalit K.; Li, Guanguan; Tiruveedhula, V. V. N. Phani Babu; Rashid, Farjana; Mian, Md Yeunus; Jahan, Rajwana; Sharmin, Dishary; Cerne, Rok; Cook, James M.; Witkin, Jeffrey M. (2020-09-02). "Imidazodiazepine Anticonvulsant, KRM-II-81, Produces Novel, Non-diazepam-like Antiseizure Effects". ACS Chemical Neuroscience. 11 (17): 2624–2637. doi:10.1021/acschemneuro.0c00295. hdl:1805/28047. ISSN 1948-7193. PMID 32786313. S2CID 221123396.